Table 1.
Absolute and relative development of patient number of gynecology, obstetrics, and gyne-oncology patient collectives.
| Patient Number, 2017–2021 | Absolute Number | Relative Change in % | Share of Overall Gyne-Oncology Cases, in % | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 2017 | 2018 | 2019 | 2020 | 2021 | 18 to 19 | 19 to 20 | 19 to 21 | ||
| Main Patient Collectives | |||||||||
| nGynecology | 1767 | 1879 | 2045 | 1918 | 1944 | 9% | −6% | −5% | n.a. |
| nObstetrics | 3565 | 3699 | 4150 | 4558 | 5000 | 12% | 10% | 20% | n.a. |
| nGyne-Oncology | 652 | 658 | 702 | 662 | 685 | 7% | −6% | −2% | n.a. |
| Gyne-Oncology Patient Collective | |||||||||
| C50 Malignant neoplasm of the breast | 407 | 424 | 461 | 429 | 469 | 9% | −7% | 2% | 68.5% |
| C51 Malignant neoplasm of the vulva | 36 | 33 | 40 | 47 | 26 | 21% | 18% | −35% | 3.8% |
| C52 Malignant neoplasm of the vagina | 5 | 3 | 5 | 7 | 7 | 67% | 40% | 40% | 1.0% |
| C53 Malignant neoplasm of the cervix | 45 | 46 | 39 | 32 | 30 | −15% | −18% | −23% | 4.4% |
| C54 Malignant neoplasm of the corpus uteri | 80 | 70 | 67 | 61 | 57 | −4% | −9% | −15% | 8.3% |
| C56 Malignant neoplasm of the ovary | 72 | 81 | 85 | 73 | 91 | 5% | −14% | 7% | 13.3% |
| C57 Malignant neoplasm of other and unspecified female genital organs | 3 | 1 | 5 | 6 | 2 | 400% | 20% | −60% | 0.3% |
| C58 Malignant neoplasm of the placenta | 4 | 0 | 0 | 7 | 3 | n.a. | n.a. | n.a. | 0.4% |
n.a. = not applicable, red color indicating a decrease, green color indicating an increase.